Latin American consensus on hypertension in patients with diabetes type 2 and metabolic syndrome

Journal of Hypertension

Volumn 31, Issue 2, 2013, Pages 223-238

  López Jaramillo, Patricio ^a   Sánchez, Ramiro A ^b   Diaz, Margarita ^c   Cobos, Leonardo ^d   Bryce, Alfonso ^e   Carrillo, Jose Z Parra ^f   Lizcano, Fernando ^g   Lanas, Fernando ^h   Sinay, Isaac ⁱ   Sierra, Iván D ^j   Peñaherrera, Ernesto ^k   Bendersky, Mario ^l   Schmid, Helena ^m   Botero, Rodrigo ⁿ   Urina, Manuel ^o   Lara, Joffre ^p   Foss, Milton C ^q   Márquez, Gustavo ^r   Harrap, Stephen ^s   Ramírez, Agustín J ^b   Zanchetti, Alberto ^t   more..

^a UNIVERSIDAD DE SANTANDER   (Colombia)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

^c Clínica Platinum   (Uruguay)

^d Colegio Panamericano Del Endotelio ^*  (Chile)

^e CardioGolf   (Peru)

^f UNIVERSITY OF GUADALAJARA   (Mexico)

^g UNIVERSIDAD DE LA SABANA   (Colombia)

^h UNIVERSIDAD DE LA FRONTERA   (Chile)

ⁱ INSTITUTO CARDIOVASCULAR DE BUENOS AIRES   (Argentina)

^j Asociacion Latinoamericana de Diabetes   (Colombia)

^k HOSPITAL LUIS VERNAZA   (Ecuador)

^l UNIVERSITY OF CÓRDOBA   (Spain)

^m FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

ⁿ Centro Medico   (Colombia)

^o Sociedad Colombiana de Ortopedia   (Colombia)

^p Sociedad Ecuatoriana de Aterosclerosis   (Ecuador)

^q UNIVERSITY OF SÃO PAULO   (Brazil)

^r Federation Diabetologica Colombiana   (Colombia)

^s UNIVERSITY OF MELBOURNE   (Australia)

^t ISTITUTO AUXOLOGICO ITALIANO   (Italy)

more..

Author keywords

arterial hypertension; diabetes; Latin American consensus; metabolic syndrome

Indexed keywords

ALISKIREN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ABDOMINAL OBESITY; ALCOHOL CONSUMPTION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONSENSUS; DIABETIC NEPHROPATHY; DIET THERAPY; DISEASE PREDISPOSITION; DNA METHYLATION; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EPIGENETICS; ETHNIC DIFFERENCE; ETHNICITY; FAMILY HISTORY; GENE EXPRESSION; GERIATRIC PATIENT; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HIGH RISK POPULATION; HUMAN; HYPERINSULINEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LOWEST INCOME GROUP; MALNUTRITION; MEAN ARTERIAL PRESSURE; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RURAL POPULATION; SEDENTARY LIFESTYLE; SOCIAL STATUS; SOUTH AND CENTRAL AMERICA; SYSTOLIC HYPERTENSION; URBAN POPULATION; WAIST CIRCUMFERENCE;

EID: 84872843499     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32835c5444     Document Type: Review

References (144)

1. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21:1983-1992.
2. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21:1011-1053.
3. Delamothe T. Wanted: guidelines that doctors will follow. BMJ 1993; 307:218.
4. McColl A, Smith H, White P, Field J. General practitioners' perceptions of the route to evidence based medicine: a questionnaire survey. BMJ 1998; 316:361-365.
5. Woolf SH. Practice guidelines, a new reality in medicine. II. Methods of developing guidelines. Arch Intern Med 1992; 152:946-952.
6. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PA, Rubin HR. Why don't physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999; 282:1458-1465.
7. World Health Organization. Preventing chronic diseases: a vital investment: WHO global report. Geneva: World Health Organization; 2005 pp. 1-13 http://www.who.int/chp/chronic-disease-report/en/. [Accessed 12 June 2012]
8. Americas: a growing urban population that is growing old. Washington: OPS; 2002. http://www.paho.org/Spanish/DBI/MDS/Press1-SEA-2002.htm. [Accessed 12 June 2012]
9. Health in the Americas 2007. Washington: OPS; 2007. http://www. paho.org/hia/home.html. [Accessed 12 June 2012].
10. Sánchez RA, Ayala M, Baglivo H, Velázquez C, Burlando G, Kolmann O, et al., on behalf of the Latin American expert Group. Latin American guidelines on hypertension. J Hypertens 2009; 27:905-922.
11. Ezzati M, Lopez AD, Rodgers A, Van der Hoorn S, Murray CJ, Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet 2002; 360:1347-1360.
12. Schargrodsky H, Hernández-Hernández R, Champagne BM, Silva H, Vinueza R, Silva-Ayçaguer LC, et al., for the CARMELA study. CARMELA: assessment of the CV risk in seven Latin American cities. Am J Med 2008; 121:58-65.
13. Barreto S, Azeredo V, Oliveira J, Guerra H, Guati-Mosim P, Furtado M. Hypertension and clustering of cardiovascular risk factors in a community in southeast Brazil. The Bambuí Health and Ageing Study. Arq Bras Cardiol 2001; 77:576-581.
14. Jiménez J, Palacios M, Cañete F, Barriocanal L, Medina U, Figueredo R, et al. Prevalence of diabetes mellitus and associated cardiovascular risk factors in an adult urban population in Paraguay. Diabetic Med 1998; 15:334-338.
15. Fasce E, Campos I, Ibañez P, Flores M, Zarate H, Román O, Fasce F. Trends in prevalence, awareness, treatment and control of hypertension in urban communities in Chile. J Hypertens 2007; 25:1807-1811.
16. Guerrero-Romero F, Rodríguez M. Prevalence of hypertension and associated factors in a rural poor population. Salud Pública México 1998; 40:339-346.
17. Teo K, Chow CK, Vaz M, Rangarajan S, Yusuf S; PURE Investigators-Writing Group. The Prospective Urban Rural Epidemiology (PURE) study: examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries. Am Heart J 2009; 158:1-7.
18. Sempértegui F, Estrella B, Tucker KL, Hamer DH, Narvaez X, Sempe ́rtegui M, et al. Metabolic syndrome in the elderly living in marginal peri-urban communities in Quito, Ecuador. Public Health Nutr 2011; 14:758-767.
19. Alvarez C, Salazar R, Galindez J, Rangel F, Castañeda ML, Lopardo G, et al. Metabolic syndrome in HIV-infected patients receiving antiretroviral therapy in Latin America. Braz J Infect Dis 2010; 14:256-263.
20. Bermúdez V, Marcano RP, Cano C, Arráiz N, Amell A, Cabrera M, et al. The Maracaibo city metabolic syndrome prevalence study: design and scope. Am J Ther 2010; 17:288-294.
21. Escobedo J, Schargrodsky H, Champagne B, Silva H, Boissonnet CP, Vinueza R, et al. Prevalence of the metabolic syndrome in Latin America and its association with sub-clinical carotid atherosclerosis: the CARMELA cross sectional study. Cardiovasc Diabetol 2009; 26:8-52.
22. Caceres M, Teran CG, Rodriguez S, Medina M. Prevalence of insulin resistance and its association with metabolic syndrome criteria among Bolivian children and adolescents with obesity. BMC Pediatr 2008; 8:31.
23. Royer M, Castelo-Branco C, Blümel JE, Chedraui PA, Danckers L, Bencosme A, et al., Collaborative Group for Research of the Climacteric in Latin America. The USA National Cholesterol Education Programme Adult Treatment Panel III (NCEP ATP III): prevalence of the metabolic syndrome in postmenopausal Latin American women. Climacteric 2007; 10:164-170.
24. Bustos P, da Silva AA, Amigo H, Bettiol H, Barbieri MA. Metabolic syndrome in young adults from two socio-economic Latin American settings. Nutr Metab Cardiovasc Dis 2007; 17:581-589.
25. Rueda-Clausen C, Silva F, López-Jaramillo P. Epidemic of obesity and overweigh in Latin America and the Caribbean. Int J Cardiol 2008; 123:111-112.
26. Garcia RG, Pérez M, Maas R, Schwedhelm E, Böger RH, López-Jaramillo P. Plasma concentrations of asymmetric dimethylarginine (ADMA) in metabolic syndrome. Int J Cardiol 2007; 122:176-178.
27. López-Jaramillo P, Rueda-Clausen C, Silva FA. The utility of different definitions of metabolic syndrome in Andean population. Int J Cardiol 2007; 116:421-422.
28. Garcia RG, Cifuentes AE, Caballero RS, Sánchez L, López-Jaramillo P. A proposal for an appropriate central obesity diagnosis in Latin American population. Int J Cardiol 2005; 110:263-264.
29. Pérez M, Casas JP, Cubillos LA, Serrano NC, Silva FA, Morillo CA, et al. Using waist circumference as screening tool to identify Colombian subjects at cardiovascular risk. Eur J Cardiovasc Prev Rehab 2003; 10:328-335.
30. Pinzón JB, Serrano NC, Díaz LA, Mantilla G, Velasco HM, Martínez LX, et al. Impact of the new definitions in the prevalence of the metabolic syndrome in an adult population at Bucaramanga, Colombia. Biome ́dica 2007; 27:172-179.
31. Piegas LS, Avenzum A, Pereira JC, Neto JM, Hoepfner C, Farran JA, et al. Risk factors for myocardial infarction in Brazil. Am Heart J 2003; 146:331-338.
32. Messiah SE, Carrillo-Iregui A, Garibay-Nieto N, López-Mitnik G, Cossio S, Arheart KL. Prevalence of metabolic syndrome in USborn Latin and Caribbean youth. J Immigr Minor Health 2009; 11:366-371.
33. Velásquez-Meléndez G, Kac G, Valente JG, Tavares R, Silva CQ, Garcia ES. Evaluation of waist circumference to predict general obesity and arterial hypertension in women in Greater Metropolitan Belo Horizonte, Brazil. Cad Saude Publica 2002; 18:765-771.
34. Berber A, Gómez Santos R, Fanghanel G, Sanchez-Reyes L. Anthropometric indexes in the prediction of type 2 diabetes mellitus, hypertension and dyslipidaemia in a Mexican population. Int J Obes Relat Metab Disord 2001; 25:1794-1799.
35. Kabagambe EK, Baylin A, Campos H. Nonfatal acute myocardial infarction in Costa Rica: modifiable risk factors, population attributable risk, and adherence to dietary guidelines. Circulation 2007; 115:1075-1081.
36. Manzur F, Alvear C, Alayón A. Phenotypic and metabolic characterization of the metabolic syndrome in Cartagena de Indias. Rev Colomb Cardiol 2008; 15:97-101.
37. Sánchez F, Jaramillo N, Vanegas A, Echeverría JG, León AC, Echeverría E, et al. Prevalence and behaviour of risk factors in metabolic syndrome according to different age intervals, in a female cohort of the area of influence of the Clínica de las Américas in Medellín, Colombia. Rev Colomb Cardiol 2008; 15:102-110.
38. Villegas A, Botero J, Arango I, Arias S, Toro M. Prevalence of metabolic syndrome on El Retiro, Antioquia, Colombia. Iatreia 2003; 16:291-297.
39. Merchán A. Metabolic syndrome and cardiovascular risk. Acta Med Colomb 2005; 30:150-154.
40. Lombo B, Villalobos C, Tique C, Satizábal C, Franco C. Metabolic syndrome prevalence in patients attending the hypertension clinic at the Fundación Santa Fe de Bogotá. Rev Colomb Cardiol 2006; 12:472-478.
41. Aschner P. Metabolic síndrome in a rural and urban population in the Colombian región of the Andes. Rev Med 2007; 15:154-162.
42. Márquez-Sandoval F, Macedo-Ojeda G, Viramontes-Hörner D, Ferna ́ndezBallart JD, Salas Salvadó J, Vizmanos B. The prevalence of metabolic syndrome in Latin America: a systematic review. Public Health Nutr 2011; 14:1702-1713.
43. Guerrero-Romero F, Rodríguez M, Sandoval F, Alvarado R. Prevalence of hypertension in indigenous inhabitants of traditional communities from north of Mexico. J Hum Hypertens 2000; 14:555-559.
44. Sichieri R. Dietary patterns and their association with obesity in the Brazilian city of Rio de Janeiro. Obes Res 2002; 10:42-48.
45. Arroyo P, Loria A, Fernandez V, Flegal KM, Kuri P. Prevalence of preobesity in urban adult Mexicans in comparison with other large surveys. Obes Res 2000; 8:179-185.
46. Sereday M, Gonzalez C, Giorgini P, De Loredo L, Braguinsky J, Cobeñas C, et al. Prevalence of diabetes and obesity in the central area of Argentina. Diabetes Metab 2003; 29:5S28-15S.
47. Wilks R, Rotimit C, Bennet F, McFarlane-Anderson N, Kaufmant JS, Anderson SG, et al. Diabetes in the Caribbean: results of a population survey from Spanish Town, Jamaica. Diab Med 1999; 16:875-883.
48. Piskorz D. Risk factors in Rosario city. Results of FAROS study. Revista de la Federación Argentina de Cardiología 1999; 64:245-251.
49. Avila Curiel A, Shamah-Levy T, Chávez-Villasana A, Galindo Gómez C. Urban survey of nutrition and food in the metropolitan area of Mexico city 2002. México DF: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Instituto Nacional de Salud Pú blica; 2003.
50. De Onis M, Blössnner M. Prevalence and trends of overweight among preschool children in developing countries. Am J Clin Nutr 2000; 72:1032-1039.
51. Martorell R, Kettel Khan L, Hughes M, Grummer-Strawn LM. Obesity in Latin American women and children. J Nut 1998; 128:1464-1473.
52. Monteiro CA. Epidemiologia da Obesidade. In: Halpern A, Matos AFG, Suplicy H, Mancini MC, Zanella MT, editors. Obesidade. São Paulo: Editorial Lemos; 1998. pp.15-30.
53. Pisabarro R, Gutiérrez M, Bermúdez C, Préndez D, Recalde A, Chaftare Y, Manfredi A. Second National survey of obesity and over-weight (ENSO) in adults. Rev Med Urug 2009; 25:14-26.
54. Orduñez P, Espinosa A, Cooper R, Kaufman J, Nieto F. Hypertension in Cuba: evidence of narrow black-white difference. J Hum Hypertens 1998; 12:111-116.
55. Magalhães N, Pozzan R, Brandão AA, Cerqueira R, Rousoulieres A, Szwarcwald C, Brandão A. Early blood pressure level as a mark of familial aggregation of metabolic cardiovascular risk factors. The Rio de Janeiro Study. J Hypertens 1998; 6:1885-1889.
56. Díaz ME. Hypertension and obesity. J Hum Hypertens 2002; 16 (Suppl 1):S18-S22.
57. Filozof C, Gonzalez C, Sereday M, Mazza C, Braguinsky J. Obesity prevalence and trends in Latin American countries. Obes Rev 2001; 2:99-106.
58. Samper-Ternent R, Michaels-Obregon A, Wong R. Coexistence of obesity and anemia in older Mexican adults. Ageing Int 2011; 37:104-117.
59. Monteiro CA, Moura EC, Conde WL, Popkin BM. Socioeconomic status and obesity in adult populations of developing countries: a review. Bull World Health Organ 2004; 82:940-946.
60. Monteiro CA, Conde WL, Lu B, Popkin BM. Obesity and inequities in health in the developing world. Int J Obes Relat Metab Disord 2004; 28:1181-1186.
61. Williams K, Stern MP, Gonzalez-Villalpando C. Secular trends in obesity in Mexico City and in San Antonio. Nutr Rev 2004; 62:S158-S162.
62. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al., Harmonizing the metabolic syndrome. A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120:1640-1645.
63. Reaven GM. Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease. J Clin Endocrinol Metab 2003; 88:2399-2403.
64. Aschner P, Buendía R, Brajkovich I, Gonzalez A, Figueredo R, Juarez XE, et al. Determination of the cut-off point for waist circumference that establishes the presence of abdominal obesity in Latin American men and women. Diabetes Res Clin Pract 2011; 93:243-247.
65. American Diabetes Association. Executive summary: standards of medical care in diabetes. 2010. Diabetes Care 2010; 33(Suppl 1):S4-S10.
66. Schriger DL, Lorber B. Lowering the cut point for impaired fasting glucose: where is the evidence? Where is the logic? Diabetes Care 2004; 27:592-601.
67. Rutter MK, Nesto RW. Blood pressure, lipids and glucose in type 2 diabetes: how low should we go? Re-discovering personalized care. Eur Heart J 2011; 32:2247-2255.
68. Jonsson B. Revealing the cost of Type II diabetes in Europe. Diabetologia 2002; 45:S5-S12.
69. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 report. JAMA 2003; 289:2560-2572.
70. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25:1105-1187.
71. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caufield MJ, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27:2121-2158.
72. Staessen JA, Asmar R, De Buyzere M, Imai Y, Parati G, Shimada K, et al. Participants of the 2001 Consensus Conference on Ambulatory Blood Pressure Monitoring. Task Force II. Blood pressure measurement and cardiovascular outcome. Blood Press Monit 2001; 6:355-370.
73. O'Brien E, Asmar R, Beilin L, Imai Y, Mallion JM, Mancia G, et al. European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 2003; 21:821-848.
74. Bonow RO, Mitch WE, Nesto RW, O'Gara PT, Becker RC, Clark LT, et al. Prevention conference VI. Diabetes and cardiovascular disease. Writing Group V: management of cardiovascular-renal complications. Circulation 2002; 105:159-164.
75. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis 2000; 36:646-661.
76. DeFronzo RA. Diabetic nephropathy: etiologic and therapeutic considerations. Diabetes Rev 1995; 3:510-564.
77. Malmberg K, Norhammar A, Wedel H, Ryden L. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long term results from the Diabetes and Insulin-glucose Infusion in Acute Myocardial Infarction (DIGAMI study). Circulation 1999; 99:2626-2632.
78. Colwell JA. Aspirin therapy in diabetes (technical review). Diabetes Care 1997; 20:1767-1771.
79. McDonagh TA, Morrison CE, Lawrence A, Ford I, Tunstall-Pedoe H, McMurray JJ, Dargie HJ. Symptomatic and asymptomatic left ventricular systolic dysfunction in an urban population. Lancet 1997; 350:829-833.
80. Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, Selby JV. Glycaemic control and HF among adult patients with diabetes. Circulation 2001; 103:2668-2673.
81. Bell DS. Heart failure: the frequent, forgotten and often fatal complication of diabetes. Diabetes Care 2003; 26:2433-2441.
82. Marantz PR, Tobin JN, Wassertheil-Smoller S, Steingart RM, Wexler JP, Budner N, et al. The relationship between left ventricular function and congestive HF diagnosed by clinical criteria. Circulation 1988; 77:607-612.
83. Kasrapanayiotides T, Piechowski-Jozwiak B, Van Melle G, Bogousslavsky J, Devuyst G. Stroke patterns, etiology and prognosis in patients with diabetes mellitus. Neurology 2004; 62:1558-1562.
84. Megherbi SE, Milan C, Minier D, Couvreur G, Osseby GV, Tilling K, et al. Association between diabetes and stroke subtype on survival and functional outcome 3 months after stroke: data from the European BIOMED Stroke Project. Stroke 2003; 34:688-694.
85. Stevens RJ, Coleman RL, Adler AI, Stratton IM, Matthews DR, Holman RR. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care 2004; 27:201-207.
86. Shepard R, Balady G. Exercise as cardiovascular therapy. Circulation 1999; 99:963-972.
87. American Diabetes Association. Position statement. Diabetes mellitus and exercise. Diabetes Care 2000; 23(Suppl 1):S50-S54.
88. Walker KZ, Piers LS, Putt RS, Jones JA, O,Dea K. Effects of regular walking on cardiovascular risk factors and body composition in normoglycaemic woman and woman with type 2 diabetes. Diabetes Care 1999; 22:555-561.
89. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-1762.
90. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317:703-713.
91. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 1996; 276:1886-1892.
92. Tuomilehto J, Rastenyte D, Birkenhäger WH, Thijs L, Antikainen R, Bulpitt CJ, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999; 340:677-684.
93. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000; 23 (Suppl 2):S54-S64.
94. Heart Outcomes Prevention Evaluation (HOPE) Study investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICROHOPE substudy. Lancet 2000; 355:253-259.
95. Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, Pepine CJ. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010; 304:61-68.
96. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 2009; 27:923-934.
97. ACCORD Study group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362:1575-1585.
98. Bangalore S, Kumar S, Lobach I, Messerli FH. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose: observation from traditional and Bayesian random-effects metaanalysis of randomized trials. Circulation 2011; 123:2799-2810.
99. Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens 2011; 29:1169-1253.
100. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, et al. ADVANCE Collaborative Group. Effects of a fixed combination of perindropil and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial). Lancet 2007; 370:829-840.
101. Lewis JB. Blood pressure control in chronic kidney disease: is less really more? J Am Soc Nephrol 2010; 21:1086-1092.
102. Turnbull F, Neal B, Ninomiya T, Algert C, Arima H, et al., Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165:1410-1419.
103. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al., ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
104. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359:2417-2428.
105. Parving HH, Brenner BM, McMurray JJC, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal endpoints in a trial of Aliskiren for type-2 diabetes. N Engl J Med 2012; 367:2204-2213.
106. Stears AJ, Woods SH, Watts M, Burton TJ, Graggaber J, Mir FA, Brown MJ. A double-blind, placebo-controlled, crossover trial comparing the effects of amiloride and hydrochlorothiazide on glucose tolerance in patients with essential hypertension. Hypertension 2012; 59:934-942.
107. Central Intelligence Agency-CIA. The World factbook. Washington, DC: Central Intelligence Agency-CIA; 2012. https://www.cia.gov/library/publications/ the-world-factbook/wfbExt/region-soa.html. [Accessed 10 August 2012].
108. Sanchez-Johnsen LA, Fitzgibbon ML, Martinovich Z, Stolley MR, Dyer AR, Van Horn L. Ethnic differences in correlates of obesity between Latin-American and black women. Obes Res 2004; 12:652-660.
109. Barcelo A, Gregg EW, Partor-Valero M, Robles SC. Waist circumference, BMI and the prevalence of self-reported diabetes among the elderly of the United States and six cities of Latin American and the Caribbean. Diabetes Res Clin Pract 2007; 78:418-427.
110. Anselmi M, Avanzini F, Moreira JM, Montalvo G, Armani D, Prandi R, et al. Treatment and control of arterial hypertension in a rural community in Ecuador. Lancet 2003; 36:1186-1187.
111. Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm RH Jr, et al. Management of High Blood Pressure in Blacks. An Update of the International Society on Hypertension in Blacks Consensus Statement on behalf of the International Society on Hypertension in Blacks. Hypertension 2010; 56:780-800.
112. Burke GL, Savage PJ, Manolio TA, Sprafka JM, Wagenknecht LE, Sidney S, et al. Correlates of obesity in young black and white women: the CARDIA Study. Am J Public Health 1992; 82:1621-1625.
113. Sharp TA, Bell ML, Grunwald GK, Schmitz KH, Sidney S, Lewis CE, et al. Differences in resting metabolic rate between white and African-American young adults. Obes Res 2002; 10:726-732.
114. McVlellan W, Tuttle E, Issa A. Racial differences in the incidence of hypertensive end-stage renal disease. Am J Kidney Dis 1998; 12:285-290.
115. Lopes AA, Port FK. The low birth weight hypothesis as a plausible explanation for the black/white differences in hypertension, noninsulin-dependent diabetes, and end-stage renal disease. Am J Kidney Dis 1995; 25:350.
116. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart diseases and stroke statistics: 2011 update a report from de American Heart Association. Circulation 2011; 123:18-1209.
117. Sareli P, Radevski IV, Valtchanova ZP, Libhaber E, Candy GP, Den Hond E, et al. Efficacy of different drug classes used to initiate antihypertensive treatment in black subjects: results of a randomized trial in Johannesburg, South Africa. Arch Intern Med 2001; 161:965-971.
118. Wright JT Jr, Dunn JK, Cutler JA, Davis BR, Cushman WC, Ford CE, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005; 293: 1595-1608.
119. Brown NJ, Ray WA, Snowden M, Griffin MR. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 1996; 60:8-13.
120. Medina-Lezama J, Zea-Diaz H, Morey-Vargas OL, Bolaños-Salazar JF, Postigo-Macdowall M, Paredes-Diaz S, et al. Prevalence and patterns of hypertension in Peruvian Andean Hispanics: the PREVENCION study. J Am Soc Hypertens 2007; 1:216-225.
121. Agusti R. Epidemiology of hypertension in Peru. Acta Med Per 2006; 23:69-75.
122. Organización Panamericana de la Salud. OPS data base of basic indicators of heath http://www.paho.org/spanish/dd/ais/cp-152. htm. [Accessed 10 September 2012].
123. Vasan RS, Beiser A, Seshadri S, Larson MG, Kannel WB, D'Agostino RB, Levy D. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA 2002; 287:1003-1010.
124. Benetos A, Safar M, Rudnichi A, Smulyan H, Richard JL, Ducimetiére P, Guize J. Pulse pressure: a predictor of long-term cardiovascular mortality in a French male population. Hypertension 1997; 30:1410-1415.
125. Silagy CA, McNeil JJ, Farish S, Mc Grath BP. Comparation of repeated measurement of ambulatory and clinic blood pressure readings in isolated systolic hypertension. Clin Exp Hypertens 1995; 15:895-909.
126. Wiinberg N, Hoegholm A, Christensen HR, Bang LE, Mikkelsen KL, Nielsen PE, et al. 24-h-ambulatory blood pressure in 352 normal Danish subjects, related to age and gender. Am J Hypertens 1995; 8:978-986.
127. Kario K, Pickering TG, Matsuo T, Hoshide S, Schwartz JE, Shimada K. Stroke prognosis and abnormal nocturnal blood pressure falls in older hypertensive. Hypertension 2001; 38:852-857.
128. Kario K, Pickering TG, Umeda Y, Hoshide S, Hoshide Y, Morinari M, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107:1401-1406.
129. Verdecchia P, Angeli F, Mazzotta G, Garofoli M, Ramundo E, Gentile G, et al. Day-night dip and early-morning surge in blood pressure in hypertension: prognostic implications.Hypertension 2012; 60:34-42.
130. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al., HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Eng J Med 2008; 358:1887-1898.
131. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265:3255-3264.
132. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350:757-764.
133. Liu L, Wang JG, Gong L, Liu G, Staessen JA. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension, Systolic Hypertension in China (SYST-CHINA) Collaborative Group. J Hypertension 1998; 16:1823-1829.
134. Lopez-Jaramillo P, Lahera V, Lopez-Lopez J. Epidemic of cardiometabolic diseases: a Latin American point of view. Ther Adv Cardiovasc Dis 2011; 5:119-131.
135. López-Jaramillo P, Silva SY, Rodríguez Salamanca N, Duran A, Mosquera W, Castillo V. Are nutrition-induced epigenetic changes the link between socioeconomic pathology and cardiovascular diseases? Am J Therap 2008; 15:362-372.
136. López-Jaramillo P. Cardio-metabolic disease in Latin America: the role of fetal programming in response to maternal malnutrition. Rev Esp Cardiol 2009; 62:670-676.
137. Fernandes MT, Sesso R, Martins PA, Sawaya AL. Increased blood pressure in adolescents of socioeconomic status with short stature. Pediatr Nephrol 2003; 18:435-439.
138. Florêncio TT, Ferreira HS, Cavalcante JC, Sawaya AL. Short stature, obesity and arterial hypertension in a very low income population in North-eastern Brazil. Nutr Metab Cardiovasc Dis 2004; 14:26-33.
139. Ferreira HS, Moura FA, Cabral CR Jr, Florêncio TM, Vieira RC, de Assunção ML. Short stature of mothers from an area endemic for under-nutrition is associated with obesity, hypertension and stunted children: a population-based study in the semi-arid region of Alagoas, Northeast Brazil. Br J Nutr 2009; 101:1239-1245.
140. López-Jaramillo P, Herrera E, Garcia RG, Camacho PA, Castillo VR. Inter-relationships between body mass index, C-reactive protein and blood pressure in a Hispanic pediatric population. Am J Hypertens 2008; 21:527-532.
141. Franco MC, Casarini DE, Carneiro-Ramos MS, Sawaya AL, Barreto-Chaves ML, Sesso R. Circulating renin-angiotensin system and catecholamines in childhood: is there a role for birth weight? Clin Sci (Lond) 2008; 114:375-380.
142. Febba A, Sesso R, Barreto GP, Liboni CS, Franco MC, Casarini DE. Stunting growth: association of the blood pressure levels and ACE activity in early childhood. Pediatr Nephrol 2009; 24:379-386.
143. González-Barranco J, Ríos-Torres JM, Castillo- Martínez L, López-Alvarenga JC, Aguilar-Salinas CA, Bouchard C, et al. Effect of malnutrition during the first year of life on adult plasma insulin and glucose tolerance. Metabolism 2003; 52:1005-1011.
144. Lopez-Jaramillo P. Defining the research priorities to fight the burden of cardiovascular diseases in Latin America. J Hypertens 2008; 26:1886-1889.